Oral or intravenous trimethoprim-sulfamethoxazole therapy for shigellosis

J. D. Nelson; H. Kusmiesz; S. Shelton

doi:10.1093/clinids/4.2.546

Oral or intravenous trimethoprim-sulfamethoxazole therapy for shigellosis

J. D. Nelson, H. Kusmiesz, S. Shelton

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

A review of the literature concerning shigellosis treated with trimethoprim-sulfamethoxazole (TMP-SMZ) revealed comparative studies of 149 cases and noncomparative studies of 147 cases. Bacteriologic and clinical success rates were ⩾90% and TMP-SMZ compared favorably with alternative drug therapy. In the present study TMP-SMZ was given intravenously as initial therapy to 11 children hospitalized for severe shigella colitis. Bacteriologic and clinical responses were comparable to those observed with oral TMP-SMZ therapy. Pharmacokinetic studies revealed substantial differences between the responses of these children and those reported for adult patients; a higher ratio of SMZ to TMP (50:1) was found in children. It is concluded that TMP-SMZ is effective therapy for shigellosis and is the drug of choice in areas where ampicillin resistance is prevalent.

Original language	English (US)
Pages (from-to)	546-550
Number of pages	5
Journal	Reviews of infectious diseases
Volume	4
Issue number	2
DOIs	https://doi.org/10.1093/clinids/4.2.546
State	Published - Mar 1982

ASJC Scopus subject areas

Microbiology (medical)

Access to Document

10.1093/clinids/4.2.546

Cite this

@article{9a0b8249674d4b26810c274223729706,

title = "Oral or intravenous trimethoprim-sulfamethoxazole therapy for shigellosis",

abstract = "A review of the literature concerning shigellosis treated with trimethoprim-sulfamethoxazole (TMP-SMZ) revealed comparative studies of 149 cases and noncomparative studies of 147 cases. Bacteriologic and clinical success rates were ⩾90% and TMP-SMZ compared favorably with alternative drug therapy. In the present study TMP-SMZ was given intravenously as initial therapy to 11 children hospitalized for severe shigella colitis. Bacteriologic and clinical responses were comparable to those observed with oral TMP-SMZ therapy. Pharmacokinetic studies revealed substantial differences between the responses of these children and those reported for adult patients; a higher ratio of SMZ to TMP (50:1) was found in children. It is concluded that TMP-SMZ is effective therapy for shigellosis and is the drug of choice in areas where ampicillin resistance is prevalent.",

author = "Nelson, {J. D.} and H. Kusmiesz and S. Shelton",

year = "1982",

month = mar,

doi = "10.1093/clinids/4.2.546",

language = "English (US)",

volume = "4",

pages = "546--550",

journal = "Reviews of infectious diseases",

issn = "0162-0886",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Oral or intravenous trimethoprim-sulfamethoxazole therapy for shigellosis

AU - Nelson, J. D.

AU - Kusmiesz, H.

AU - Shelton, S.

PY - 1982/3

Y1 - 1982/3

N2 - A review of the literature concerning shigellosis treated with trimethoprim-sulfamethoxazole (TMP-SMZ) revealed comparative studies of 149 cases and noncomparative studies of 147 cases. Bacteriologic and clinical success rates were ⩾90% and TMP-SMZ compared favorably with alternative drug therapy. In the present study TMP-SMZ was given intravenously as initial therapy to 11 children hospitalized for severe shigella colitis. Bacteriologic and clinical responses were comparable to those observed with oral TMP-SMZ therapy. Pharmacokinetic studies revealed substantial differences between the responses of these children and those reported for adult patients; a higher ratio of SMZ to TMP (50:1) was found in children. It is concluded that TMP-SMZ is effective therapy for shigellosis and is the drug of choice in areas where ampicillin resistance is prevalent.

AB - A review of the literature concerning shigellosis treated with trimethoprim-sulfamethoxazole (TMP-SMZ) revealed comparative studies of 149 cases and noncomparative studies of 147 cases. Bacteriologic and clinical success rates were ⩾90% and TMP-SMZ compared favorably with alternative drug therapy. In the present study TMP-SMZ was given intravenously as initial therapy to 11 children hospitalized for severe shigella colitis. Bacteriologic and clinical responses were comparable to those observed with oral TMP-SMZ therapy. Pharmacokinetic studies revealed substantial differences between the responses of these children and those reported for adult patients; a higher ratio of SMZ to TMP (50:1) was found in children. It is concluded that TMP-SMZ is effective therapy for shigellosis and is the drug of choice in areas where ampicillin resistance is prevalent.

UR - http://www.scopus.com/inward/record.url?scp=0020107088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020107088&partnerID=8YFLogxK

U2 - 10.1093/clinids/4.2.546

DO - 10.1093/clinids/4.2.546

M3 - Article

C2 - 6981170

AN - SCOPUS:0020107088

SN - 0162-0886

VL - 4

SP - 546

EP - 550

JO - Reviews of infectious diseases

JF - Reviews of infectious diseases

IS - 2

ER -

Oral or intravenous trimethoprim-sulfamethoxazole therapy for shigellosis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this